| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
|
Am J Cardiol
|
2003
|
5.77
|
|
2
|
Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).
|
Am J Cardiol
|
2012
|
3.23
|
|
3
|
Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia.
|
Am J Cardiol
|
2002
|
2.50
|
|
4
|
Safety considerations with niacin therapy.
|
Am J Cardiol
|
2006
|
2.30
|
|
5
|
Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
|
Clin Ther
|
2007
|
1.86
|
|
6
|
Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial.
|
J Am Coll Cardiol
|
2013
|
1.57
|
|
7
|
Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.
|
Am J Cardiol
|
2007
|
1.22
|
|
8
|
Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial.
|
Am Heart J
|
2002
|
1.21
|
|
9
|
Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia.
|
Am J Cardiol
|
2002
|
1.15
|
|
10
|
Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study).
|
Atherosclerosis
|
2007
|
1.13
|
|
11
|
Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease.
|
Am J Cardiol
|
2008
|
1.09
|
|
12
|
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.
|
Clin Drug Investig
|
2008
|
1.07
|
|
13
|
Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia.
|
Am J Cardiol
|
2008
|
1.04
|
|
14
|
Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia.
|
J Am Coll Cardiol
|
2006
|
1.01
|
|
15
|
Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome.
|
Am J Cardiol
|
2005
|
0.98
|
|
16
|
Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia.
|
J Clin Lipidol
|
2011
|
0.91
|
|
17
|
Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study.
|
Cardiovasc Diabetol
|
2013
|
0.89
|
|
18
|
Use of a treatment algorithm to achieve NCEP ATP III goals with atorvastatin.
|
J Cardiovasc Pharmacol
|
2005
|
0.85
|
|
19
|
Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study).
|
Prostaglandins Leukot Essent Fatty Acids
|
2013
|
0.83
|
|
20
|
Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects.
|
Clin Cardiol
|
2006
|
0.81
|
|
21
|
Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors.
|
Cardiol Clin
|
2008
|
0.81
|
|
22
|
Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies.
|
Clin Cardiol
|
2014
|
0.80
|
|
23
|
Treatment options for the management of hypertriglyceridemia: strategies based on the best-available evidence.
|
J Clin Lipidol
|
2012
|
0.79
|
|
24
|
Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia.
|
Coron Artery Dis
|
2004
|
0.78
|
|
25
|
Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects.
|
J Cardiovasc Pharmacol
|
2009
|
0.78
|
|
26
|
Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States.
|
Curr Med Res Opin
|
2007
|
0.78
|
|
27
|
Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia.
|
Coron Artery Dis
|
2016
|
0.77
|
|
28
|
Raisins compared with other snack effects on glycemia and blood pressure: a randomized, controlled trial.
|
Postgrad Med
|
2014
|
0.76
|
|
29
|
Results of two clinical trials on the safety and efficacy of pravastatin 80 and 160 mg per day.
|
Am J Cardiol
|
2003
|
0.76
|
|
30
|
Effectiveness and safety of laropiprant on niacin-induced flushing.
|
Am J Cardiol
|
2012
|
0.75
|
|
31
|
Authors' reply.
|
Am J Cardiol
|
2013
|
0.75
|
|
32
|
Icosabutate, a Structurally Engineered Fatty Acid, Improves the Cardiovascular Risk Profile in Statin-Treated Patients with Residual Hypertriglyceridemia.
|
Cardiology
|
2016
|
0.75
|
|
33
|
The editor's roundtable: hypertriglyceridemia.
|
Am J Cardiol
|
2013
|
0.75
|
|
34
|
Planning a clinical trial.
|
J Clin Lipidol
|
2012
|
0.75
|